Medtronic PLC $MDT is Crawford Investment Counsel Inc.’s 6th Largest Position

Crawford Investment Counsel Inc. grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 0.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,353,062 shares of the medical technology company’s stock after buying an additional 9,651 shares during the quarter. Medtronic accounts for about 2.1% of Crawford Investment Counsel Inc.’s investment portfolio, making the stock its 6th biggest position. Crawford Investment Counsel Inc. owned 0.11% of Medtronic worth $128,866,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Delos Wealth Advisors LLC purchased a new position in Medtronic during the 2nd quarter valued at $27,000. Corundum Trust Company INC purchased a new stake in Medtronic in the third quarter worth $27,000. Valley Wealth Managers Inc. bought a new stake in shares of Medtronic during the third quarter worth $29,000. Imprint Wealth LLC bought a new stake in shares of Medtronic during the third quarter worth $31,000. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medtronic during the third quarter valued at $33,000. 82.06% of the stock is owned by institutional investors.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.26% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on MDT. Wells Fargo & Company started coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. Royal Bank Of Canada boosted their price objective on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Jefferies Financial Group restated a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Robert W. Baird reduced their target price on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Finally, William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Stock Down 0.4%

NYSE:MDT opened at $87.05 on Friday. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The company has a 50-day moving average of $97.96 and a 200 day moving average of $96.87. The firm has a market cap of $111.77 billion, a PE ratio of 24.25, a price-to-earnings-growth ratio of 2.23 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter last year, the firm posted $1.38 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).